iProXProteomicsXi ZhouHomo Sapienshttp://www.iprox.org/page/project.html?id=IPX0002173000zhouxi@wh.iov.cnWuhan Institue of Virology, Chinese Academy of SciencesiProXThe coronavirus disease 2019 (COVID-19) pandemic is a global public health crisis. However, little is known about the pathogenesis and biomarkers of COVID-19. Here, we profiled host responses to COVID-19 by performing plasma proteomics of a cohort of COVID-19 patients, including non-survivors and survivors recovered from mild or severe symptoms, and uncovered numerous COVID-19-associated alterations of plasma proteins. We developed a machine-learning-based pipeline to identify 11 proteins as biomarkers and a set of biomarker combinations, which were validated by an independent cohort and accurately distinguished and predicted COVID-19 outcomes. Some of the biomarkers were further validated by enzyme-linked immunosorbent assay (ELISA) using a larger cohort. These markedly altered proteins, including the biomarkers, mediate pathophysiological pathways, such as immune or inflammatory responses, platelet degranulation and coagulation, and metabolism, that likely contribute to the pathogenesis. Our findings provide valuable knowledge about COVID-19 biomarkers and shed light on the pathogenesis and potential therapeutic targets of COVID-19.Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19.Shu Ting T, Ning Wanshan W, Wu Di D, Xu Jiqian J, Han Qiangqiang Q, Huang Muhan M, Zou Xiaojing X, Yang Qingyu Q, Yuan Yang Y, Bie Yuanyuan Y, Pan Shangwen S, Mu Jingfang J, Han Yang Y, Yang Xiaobo X, Zhou Hong H, Li Ruiting R, Ren Yujie Y, Chen Xi X, Yao Shanglong S, Qiu Yang Y, Zhang Ding-Yu DY, Xue Yu Y, Shang You Y, Zhou Xi XfalsePlasma proteomics dataset of COVID-19 patientsQuantitative proteomic analysis of plasma from different time courses of fatal, severe, and mild COVID-19 patients was performed to assess the biological changes during treatment.Mon Jun 22 00:00:00 BST 2020PXD019106960633128875